1. Revisiting the Pharmacoeconomics of HF

2. Program Goals

3. Need for Reduction in Hospitalizations of HF

4. Need for Reduction in Costs Associated With HF

5. A Large Number of Eligible Patients Are Untreated

6. The Importance of Considering Cost-Effectiveness

7. New Therapies for HF

8. Measuring Cost-Effectiveness

9. Measuring Cost-Effectiveness (cont)

10. Cost-Effectiveness of Ivabradine Greece and United Kingdom

11. Cost-Effectiveness of Ivabradine United States

12. Cost-Effectiveness of Sacubitril/ Valsartan

13. Cost-Effectiveness of Sacubitril/ Valsartan (cont)

14. Cost-Effectiveness of Sacubitril/ Valsartan (cont)

15. Ivabradine and Sacubitril/Valsartan Decrease Risk of Recurrent Hospitalizations for Worsening HF

16. The Lapse Between Research and Clinical Practice

17. Bringing New Drugs Into Clinical Care

18. Abbreviations